| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Profit before tax | -1.5 | -9.9 |
| Net income | -1.4 | -9.9 |
| EPS (diluted, $ a share) | $-0.26 | $-4.41 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: NEUP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Neuphoria Therapeutics Inc.: key numbers
- Share price
- $2.27Close, Nov 17
- Market cap
- $12.3M
- Shares outstanding
- 5.41MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Neuphoria Therapeutics Inc.
All →Neuphoria Therapeutics Other 8-K Filing
Neuphoria Therapeutics Inc. has extended its existing shareholder rights agreement (poison pill) for an additional year. The amendment extends the final expiration date of the rights from October 27, 2026, to October 27, 2027. This corporate governance measure is typically used to deter unsolicited takeover attempts by making a hostile acquisition significantly more expensive.
- Counterparty
- Computershare Trust Company, N.A.
- Term
- 1 year